CY1121136T1 - Φυτικα εκχυλισματα που περιεχουν κανναβινοειδη ως νευροπροστατευτικους παραγοντες - Google Patents
Φυτικα εκχυλισματα που περιεχουν κανναβινοειδη ως νευροπροστατευτικους παραγοντεςInfo
- Publication number
- CY1121136T1 CY1121136T1 CY20181101225T CY181101225T CY1121136T1 CY 1121136 T1 CY1121136 T1 CY 1121136T1 CY 20181101225 T CY20181101225 T CY 20181101225T CY 181101225 T CY181101225 T CY 181101225T CY 1121136 T1 CY1121136 T1 CY 1121136T1
- Authority
- CY
- Cyprus
- Prior art keywords
- neuroprosperative
- factors
- extracts containing
- herbal extracts
- containing cannabinoids
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 6
- 239000003557 cannabinoid Substances 0.000 title abstract 6
- 229940065144 cannabinoids Drugs 0.000 title abstract 3
- 239000012676 herbal extract Substances 0.000 title 1
- 239000000419 plant extract Substances 0.000 abstract 3
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Η εφεύρεση σχετίζεται με τη χρήση φυτικών εκχυλισμάτων που περιέχουν κανναβινοειδή για την πρόληψη ή τη θεραπεία του νευρωνικού εκφυλισμού. Πιο συγκεκριμένα, η εφεύρεση αναφέρεται στη χρήση ενός ή περισσοτέρων φυτικών εκχυλισμάτων που περιέχουν κανναβινοειδή για την πρόληψη ή τη θεραπεία του νευρωνικού εκφυλισμού, όπου το ένα ή περισσότερα φυτικά εκχυλίσματα που περιέχουν κανναβινοειδή περιλαμβάνουν: i) ένα κλάσμα που περιέχει κανναβινοειδή, και ii) ένα κλάσμα που δεν περιέχει κανναβινοειδή.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0601013A GB2434312B (en) | 2006-01-18 | 2006-01-18 | Cannabinoid-containing plant extracts as neuroprotective agents |
EP07704916.1A EP1976506B1 (en) | 2006-01-18 | 2007-01-17 | Cannabinoid-containing plant extracts as neuroprotective agents |
PCT/GB2007/000122 WO2007083098A1 (en) | 2006-01-18 | 2007-01-17 | Cannabinoid-containing plant extracts as neuroprotective agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121136T1 true CY1121136T1 (el) | 2020-05-29 |
Family
ID=36010529
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181101225T CY1121136T1 (el) | 2006-01-18 | 2018-11-20 | Φυτικα εκχυλισματα που περιεχουν κανναβινοειδη ως νευροπροστατευτικους παραγοντες |
CY20191100987T CY1122076T1 (el) | 2006-01-18 | 2019-09-19 | Φυτικα εκχυλισματα που περιεχουν κανναβινοειδες σαν νευρο-προστατευτικοι παραγοντες |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100987T CY1122076T1 (el) | 2006-01-18 | 2019-09-19 | Φυτικα εκχυλισματα που περιεχουν κανναβινοειδες σαν νευρο-προστατευτικοι παραγοντες |
Country Status (13)
Country | Link |
---|---|
US (2) | US8673368B2 (el) |
EP (2) | EP2332533B1 (el) |
CA (1) | CA2636634C (el) |
CY (2) | CY1121136T1 (el) |
DK (2) | DK2332533T3 (el) |
ES (2) | ES2698370T3 (el) |
GB (1) | GB2434312B (el) |
HU (2) | HUE046388T2 (el) |
LT (2) | LT1976506T (el) |
PL (2) | PL2332533T3 (el) |
PT (2) | PT1976506T (el) |
SI (2) | SI1976506T1 (el) |
WO (1) | WO2007083098A1 (el) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2434312B (en) | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
GB2450753B (en) * | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
GB2451254A (en) * | 2007-07-24 | 2009-01-28 | Gw Pharma Ltd | Cannabidiol for use in the treatment of neurodegenerative conditions |
WO2010012506A1 (en) * | 2008-07-31 | 2010-02-04 | Bionorica Research Gmbh | Cannabinoids for use in treating or preventing cognitive impairment and dementia |
GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途 |
GB2479153B (en) * | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
GB2487183B (en) * | 2011-01-04 | 2018-10-03 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
US8445034B1 (en) | 2010-11-02 | 2013-05-21 | Albert L Coles, Jr. | Systems and methods for producing organic cannabis tincture |
GB201111261D0 (en) * | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
GB2514054A (en) * | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2504263B (en) | 2012-06-08 | 2015-09-16 | Gw Pharma Ltd | Synergistic therapies for neuroprotection |
EP2934512B1 (en) | 2012-12-18 | 2021-11-24 | Kotzker Consulting LLC | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
CA2902452C (en) | 2013-02-28 | 2018-09-04 | Full Spectrum Laboratories Limited | Chemical engineering processes and apparatus for the synthesis of compounds |
CA2904968A1 (en) | 2013-03-14 | 2014-10-02 | Sc Laboratories, Inc. | Bioactive concentrates and uses thereof |
US9380813B2 (en) | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
US10821240B2 (en) | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
WO2016010827A1 (en) | 2014-07-14 | 2016-01-21 | Librede Inc. | Production of cannabinoids in yeast |
US9394510B2 (en) | 2014-08-25 | 2016-07-19 | Full Spectrum Laboratories Limited | Apparatus and methods for the simultaneous production of compounds |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
WO2017066744A1 (en) * | 2015-10-16 | 2017-04-20 | Scythian Biosciences Inc. | Methods and compositions for treating traumatic brain injury |
WO2017093986A1 (en) * | 2015-12-05 | 2017-06-08 | Canabuzz-Med | Veterinary composition and methods for production and use |
US9956173B1 (en) | 2016-02-08 | 2018-05-01 | Jeff Nordahl | Packaged frozen cubes of cannabis juice purée that are non-psychoactive |
US11191794B1 (en) | 2016-02-08 | 2021-12-07 | Jeff Nordahl | Packaged hemp products formed from raw cannabis |
US11779622B1 (en) | 2016-02-08 | 2023-10-10 | Jeff Nordahl | Packaged raw cannabis powder |
US11172698B1 (en) | 2016-02-08 | 2021-11-16 | Jeff Nordahl | Pasteurized juice formed from raw cannabis |
IL307857A (en) * | 2016-03-16 | 2023-12-01 | Buzzelet Development And Technologies Ltd | Cannobinoid compounds are rich in terpenes |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2549278B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
US10143706B2 (en) | 2016-06-29 | 2018-12-04 | Cannscience Innovations, Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US9717683B1 (en) | 2016-06-29 | 2017-08-01 | Ep Pharma, Llc | Low-temperature inhalation administration of cannabinoid entities |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
JP7225103B2 (ja) * | 2016-10-11 | 2023-02-20 | ジービーエス グローバル バイオファーマ,インコーポレイテッド | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 |
US10239808B1 (en) * | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
EP3576724B1 (en) | 2017-02-01 | 2023-09-27 | GBS Global Biopharma, Inc. | Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders |
CA3053187A1 (en) * | 2017-02-09 | 2018-08-16 | Bodhi Research & Development Inc. | Cannabinoid-containing fatty acid formulations for treating disorders of the nervous system |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
BR112019019966A2 (pt) | 2017-03-24 | 2020-04-28 | Trait Biosciences Inc | biossíntese in vivo de alto nível e isolamento de canabinoides solúveis em água em sistemas de plantas |
CN107137605A (zh) * | 2017-03-27 | 2017-09-08 | 昭通天麻产业开发有限公司 | 一种由乌天麻提取物和植物大麻提取物及口服载体组成的组合物 |
WO2018205038A1 (en) * | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
WO2019014395A1 (en) | 2017-07-11 | 2019-01-17 | Trait Biosciences, Inc. | GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS |
US11905543B2 (en) | 2017-07-11 | 2024-02-20 | Trait Biosceinces, Inc. | In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures |
US11946059B2 (en) | 2017-07-11 | 2024-04-02 | Trait Biosciences, Inc. | In vivo generation of water-soluble cannabinoids in plant cell suspension cultures |
GB2564459B (en) * | 2017-07-12 | 2022-03-09 | Gw Res Ltd | Use of cannabinoids in the treatment of a neurodegenerative disease or disorder |
US10272360B2 (en) | 2017-08-05 | 2019-04-30 | Priya Naturals, Inc. | Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto |
WO2019056128A1 (en) * | 2017-09-25 | 2019-03-28 | Canopy Health Innovations | COMPOSITIONS COMPRISING CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENES AND FLAVONOIDS AND THEIR USE IN THE TREATMENT OF INSOMNIA |
US10307392B2 (en) * | 2017-10-21 | 2019-06-04 | Alexander Kariman | Compound and method for treatment of diseases and disorders |
US20190183849A1 (en) * | 2017-10-21 | 2019-06-20 | Alexander Kariman | Compound and method for treatment of diseases and disorders |
US10722545B2 (en) | 2018-01-01 | 2020-07-28 | Alexander Kariman | Compound and method for treatment of movement disorders |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
MX2020010284A (es) * | 2018-03-30 | 2021-02-18 | India Globalization Capital Inc | Método y composición para el tratamiento de los trastornos del snc. |
GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
EP3864000A4 (en) | 2018-10-10 | 2022-08-10 | Treehouse Biosciences, Inc. | CANNABIGEROL SYNTHESIS |
MX2021005474A (es) * | 2018-11-09 | 2021-09-08 | Agriculture Victoria Serv Pty | Plantas con perfil de cannabinoides enriquecido con cannabidiol. |
US20210392943A1 (en) * | 2018-11-09 | 2021-12-23 | Cronos Group Inc. | Liquid composition for an electronic vapor device |
WO2020223800A1 (en) | 2019-05-03 | 2020-11-12 | Zyus Life Sciences Inc. | Formulation for pain management |
GB2584341B (en) | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
CA3154135A1 (en) | 2019-09-16 | 2021-03-25 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
EP4121164A1 (en) * | 2020-03-17 | 2023-01-25 | Tauriga Sciences Inc. | Medicated cannabinoid compositions, methods of manufacturing, and methods of treatment |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
KR20220084761A (ko) | 2020-12-14 | 2022-06-21 | 강원대학교산학협력단 | 헴프 껍질 추출물을 포함하는 인지기능 개선용 조성물 |
CN113368086B (zh) * | 2021-08-11 | 2021-12-03 | 龙麻(上海)医药研发有限责任公司 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
WO2024033521A1 (en) | 2022-08-12 | 2024-02-15 | GW Research Limited | Oral solid dosage forms comprising cannabinoids |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2337633B (en) | 1998-05-20 | 2003-04-02 | Mitel Corp | Method of forming capacitors in a semiconductor device |
DE10051427C1 (de) | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
WO2002064109A2 (en) * | 2001-02-14 | 2002-08-22 | Gw Pharma Limited | Mucoadhesive pharmaceutical formulations |
CH695661A5 (de) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
GB2381450B (en) * | 2001-10-31 | 2006-05-31 | Gw Pharma Ltd | Compositions for administration of natural or synthetic cannabinoids by vaporisation |
DE10226494A1 (de) | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
GB2391865B (en) | 2002-08-14 | 2005-06-01 | Gw Pharma Ltd | Improvements in the extraction of pharmaceutically active components from plant materials |
CA2454644C (en) * | 2002-08-14 | 2014-09-16 | Gw Pharma Limited | Cannabinoid liquid formulations for mucosal administration |
WO2004100893A2 (en) * | 2003-05-12 | 2004-11-25 | Indevus Pharmaceuticals, Inc. | Methods for treatment of inflammatory diseases using ct-3 or analogs thereof |
US9168278B2 (en) | 2004-11-16 | 2015-10-27 | Gw Pharma Limited | Use for cannabinoid |
GB2434312B (en) | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
WO2008024490A2 (en) | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
GB2450493A (en) | 2007-06-25 | 2008-12-31 | Gw Pharma Ltd | Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors |
GB2479153B (en) | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
-
2006
- 2006-01-18 GB GB0601013A patent/GB2434312B/en active Active
-
2007
- 2007-01-17 PT PT77049161T patent/PT1976506T/pt unknown
- 2007-01-17 SI SI200732127T patent/SI1976506T1/sl unknown
- 2007-01-17 LT LTEP07704916.1T patent/LT1976506T/lt unknown
- 2007-01-17 HU HUE07704916A patent/HUE046388T2/hu unknown
- 2007-01-17 WO PCT/GB2007/000122 patent/WO2007083098A1/en active Application Filing
- 2007-01-17 EP EP10189019.2A patent/EP2332533B1/en active Active
- 2007-01-17 ES ES10189019T patent/ES2698370T3/es active Active
- 2007-01-17 EP EP07704916.1A patent/EP1976506B1/en active Active
- 2007-01-17 US US12/087,847 patent/US8673368B2/en active Active
- 2007-01-17 HU HUE10189019A patent/HUE041959T2/hu unknown
- 2007-01-17 PT PT10189019T patent/PT2332533T/pt unknown
- 2007-01-17 DK DK10189019.2T patent/DK2332533T3/en active
- 2007-01-17 ES ES07704916T patent/ES2746973T3/es active Active
- 2007-01-17 PL PL10189019T patent/PL2332533T3/pl unknown
- 2007-01-17 CA CA2636634A patent/CA2636634C/en active Active
- 2007-01-17 PL PL07704916T patent/PL1976506T3/pl unknown
- 2007-01-17 LT LTEP10189019.2T patent/LT2332533T/lt unknown
- 2007-01-17 DK DK07704916.1T patent/DK1976506T3/da active
- 2007-01-17 SI SI200732073T patent/SI2332533T1/sl unknown
-
2014
- 2014-01-24 US US14/163,019 patent/US9205063B2/en active Active
-
2018
- 2018-11-20 CY CY20181101225T patent/CY1121136T1/el unknown
-
2019
- 2019-09-19 CY CY20191100987T patent/CY1122076T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US9205063B2 (en) | 2015-12-08 |
HUE041959T2 (hu) | 2019-06-28 |
PT2332533T (pt) | 2018-11-29 |
DK2332533T3 (en) | 2018-12-10 |
ES2698370T3 (es) | 2019-02-04 |
EP1976506A1 (en) | 2008-10-08 |
EP2332533A1 (en) | 2011-06-15 |
DK1976506T3 (da) | 2019-10-07 |
US20100239693A1 (en) | 2010-09-23 |
LT2332533T (lt) | 2018-12-27 |
CA2636634A1 (en) | 2007-07-26 |
CA2636634C (en) | 2017-07-11 |
CY1122076T1 (el) | 2020-11-25 |
EP1976506B1 (en) | 2019-06-26 |
US20140377382A1 (en) | 2014-12-25 |
GB2434312B (en) | 2011-06-29 |
GB2434312A (en) | 2007-07-25 |
HUE046388T2 (hu) | 2020-03-30 |
US8673368B2 (en) | 2014-03-18 |
SI1976506T1 (sl) | 2019-11-29 |
WO2007083098A1 (en) | 2007-07-26 |
LT1976506T (lt) | 2019-10-10 |
SI2332533T1 (sl) | 2019-02-28 |
PT1976506T (pt) | 2019-10-15 |
ES2746973T3 (es) | 2020-03-09 |
PL2332533T3 (pl) | 2019-02-28 |
EP2332533B1 (en) | 2018-08-22 |
GB0601013D0 (en) | 2006-03-01 |
PL1976506T3 (pl) | 2020-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121136T1 (el) | Φυτικα εκχυλισματα που περιεχουν κανναβινοειδη ως νευροπροστατευτικους παραγοντες | |
BR112021006392A2 (pt) | moduladores da alfa-1 antitripsina | |
BR112018004620A2 (pt) | moduladores da expressão de kras | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112017000024A2 (pt) | composição para tratamento de tecidos que compreende uma nanoemulsão polimérica de aminossiloxano | |
CY1114860T1 (el) | Χρηση τετρα-καρβοξιμιδιων διθιινης για την καταπολεμηση φυτοπαθογονων μυκητων | |
BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
ES2352576T8 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana. | |
AU2016261707A8 (en) | Use of cannabis to treat fibromyalgia, methods and compositions thereof | |
CR10433A (es) | Compuestos organicos y sus usos | |
EA201200631A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
UY31145A1 (es) | Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene | |
GT201000029A (es) | Composiciones y metodos para controlar nematodos | |
ECSP10010042A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
NO20084749L (no) | Organiske forbindelser og deres anvendelser | |
BR112018015754A2 (pt) | anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1 | |
ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
WO2010034015A3 (en) | Modulating the alternative complement pathway | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
BR112012014669A2 (pt) | componente para artigo de fumar, artigo de fumar e método | |
ECSP19072372A (es) | Moduladores de la expresión de pcsk9 |